{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:25:45Z","timestamp":1790825145897,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,6]]},"DOI":"10.7759\/cureus.73156","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T19:29:37Z","timestamp":1730921377000},"source":"Crossref","is-referenced-by-count":1,"title":["The Enigma of Idiopathic Multicentric Castleman Disease: An Elusive Diagnosis"],"prefix":"10.7759","author":[{"given":"Jessica","family":"Ohemeng-Dapaah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afoma","family":"Onyechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Lacasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyotsana","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of Castleman disease","volume":"135","author":"Dispenzieri A","year":"2020","unstructured":"Dispenzieri A, Fajgenbaum DC. Overview of Castleman disease. Blood. 2020, 135:1353-64. 10.1182\/blood.2019000931","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/dmr-20-49","article-title":"A case of Castleman disease and literature review","volume":"3","author":"Jiang J","year":"2020","unstructured":"Jiang J, Hao T, Chen J, et al.. A case of Castleman disease and literature review. Dig Med Res. 2020, 3:79. 10.21037\/dmr-20-49","journal-title":"Dig Med Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.006","article-title":"Unicentric Castleman disease","volume":"32","author":"Wong RS","year":"2018","unstructured":"Wong RS. Unicentric Castleman disease. Hematol Oncol Clin North Am. 2018, 32:65-73. 10.1016\/j.hoc.2017.09.006","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00317-7","article-title":"Castleman disease","volume":"7","author":"Carbone A","year":"2021","unstructured":"Carbone A, Borok M, Damania B, et al.. Castleman disease. Nat Rev Dis Primers. 2021, 7:84. 10.1038\/s41572-021-00317-7","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2017.09.001","article-title":"Epidemiology of Castleman disease","volume":"32","author":"Simpson D","year":"2018","unstructured":"Simpson D. Epidemiology of Castleman disease. Hematol Oncol Clin North Am. 2018, 32:1-10. 10.1016\/j.hoc.2017.09.001","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834db525","article-title":"Castleman disease and associated autoimmune disease","volume":"24","author":"Muskardin TW","year":"2012","unstructured":"Muskardin TW, Peterson BA, Molitor JA. Castleman disease and associated autoimmune disease. Curr Opin Rheumatol. 2012, 24:76-83. 10.1097\/BOR.0b013e32834db525","journal-title":"Curr Opin Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum DC","year":"2017","unstructured":"Fajgenbaum DC, Uldrick TS, Bagg A, et al.. International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease. Blood. 2017, 129:1646-57. 10.1182\/blood-2016-10-746933","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1827.2000.01052.x","article-title":"Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases","volume":"50","author":"Kojima M","year":"2000","unstructured":"Kojima M, Nakamura S, Morishita Y, et al.. Reactive follicular hyperplasia in the lymph node lesions from systemic lupus erythematosus patients: a clinicopathological and immunohistological study of 21 cases. Pathol Int. 2000, 50:304-12. 10.1046\/j.1440-1827.2000.01052.x","journal-title":"Pathol Int"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000891","article-title":"Unmet clinical needs in the management of idiopathic multicentric Castleman disease: a consensus-based position paper from an ad hoc expert panel","volume":"7","author":"Zinzani PL","year":"2023","unstructured":"Zinzani PL, Paulli M, Arcaini L, et al.. Unmet clinical needs in the management of idiopathic multicentric Castleman disease: a consensus-based position paper from an ad hoc expert panel. Hemasphere. 2023, 7:e891. 10.1097\/HS9.0000000000000891","journal-title":"Hemasphere"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"van Rhee F","year":"2018","unstructured":"van Rhee F, Voorhees P, Dispenzieri A, et al.. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. Blood. 2018, 132:2115-24. 10.1182\/blood-2018-07-862334","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-12-4602","article-title":"Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease","volume":"106","author":"Nishimoto N","year":"2005","unstructured":"Nishimoto N, Kanakura Y, Aozasa K, et al.. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005, 106:2627-32. 10.1182\/blood-2004-12-4602","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2022.107282","article-title":"Castleman's disease: a rare case report and review of literature","volume":"95","author":"Saadallah MA","year":"2022","unstructured":"Saadallah MA. Castleman's disease: a rare case report and review of literature. Int J Surg Case Rep. 2022, 95:107282. 10.1016\/j.ijscr.2022.107282","journal-title":"Int J Surg Case Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197203)29:3<670::aid-cncr2820290321>3.0.co;2-#","article-title":"Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations","volume":"29","author":"Keller AR","year":"1972","unstructured":"Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972, 29:670-83. 10.1002\/1097-0142(197203)29:3&lt;670::aid-cncr2820290321&gt;3.0.co;2-#","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e318249dcdc","article-title":"Surgery in Castleman's disease: a systematic review of 404 published cases","volume":"255","author":"Talat N","year":"2012","unstructured":"Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease: a systematic review of 404 published cases. Ann Surg. 2012, 255:677-84. 10.1097\/SLA.0b013e318249dcdc","journal-title":"Ann Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20232455","article-title":"Idiopathic multicentric Castleman disease: a mysterious case of generalized lymphadenopathy","volume":"11","author":"Sebastian N","year":"2023","unstructured":"Sebastian N, Shoaib Nawaz PN, Ananthkrishnan R, Kumanan J, Lakshmanan A, Raja T. Idiopathic multicentric Castleman disease: a mysterious case of generalized lymphadenopathy. Int J Res Med Sci. 2023, 11:3087-91. 10.18203\/2320-6012.ijrms20232455","journal-title":"Int J Res Med Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7981","article-title":"A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: a case report","volume":"11","author":"Strach M","year":"2023","unstructured":"Strach M, Kuszmiersz P, Chmura \u0141, Korkosz M. A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: a case report. Clin Case Rep. 2023, 11:e7981. 10.1002\/ccr3.7981","journal-title":"Clin Case Rep"},{"key":"ref17","article-title":"Castleman's disease","volume":"43","author":"Williams DS","year":"2013","unstructured":"Williams DS. Castleman's disease. J Insur Med. 2013, 43:256-8.","journal-title":"J Insur Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman's disease: a systematic literature review","volume":"3","author":"Liu AY","year":"2016","unstructured":"Liu AY, Nabel CS, Finkelman BS, et al.. Idiopathic multicentric Castleman's disease: a systematic literature review. Lancet Haematol. 2016, 3:e163-75. 10.1016\/S2352-3026(16)00006-5","journal-title":"Lancet Haematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23291","article-title":"The clinical spectrum of Castleman's disease","volume":"87","author":"Dispenzieri A","year":"2012","unstructured":"Dispenzieri A, Armitage JO, Loe MJ, et al.. The clinical spectrum of Castleman's disease. Am J Hematol. 2012, 87:997-1002. 10.1002\/ajh.23291","journal-title":"Am J Hematol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial","volume":"15","author":"van Rhee F","year":"2014","unstructured":"van Rhee F, Wong RS, Munshi N, et al.. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014, 15:966-74. 10.1016\/S1470-2045(14)70319-5","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.5152\/TurkThoracJ.2018.18066","article-title":"Biologic agents in the treatment of multicentric Castleman disease","volume":"19","author":"Kapriniotis K","year":"2018","unstructured":"Kapriniotis K, Lampridis S, Mitsos S, Patrini D, Lawrence DR, Panagiotopoulos N. Biologic agents in the treatment of multicentric Castleman disease. Turk Thorac J. 2018, 19:220-5. 10.5152\/TurkThoracJ.2018.18066","journal-title":"Turk Thorac J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/309120-the-enigma-of-idiopathic-multicentric-castleman-disease-an-elusive-diagnosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T19:29:38Z","timestamp":1730921378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/309120-the-enigma-of-idiopathic-multicentric-castleman-disease-an-elusive-diagnosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.73156","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,6]]}}}